XML 60 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2024
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Schedule of Stock Options Granted
   
Year ended December 31, 2024
 
   
Number
of options
   
Weighted
average
exercise
price
   
Weighted average
remaining
contractual term
(in years)
   
Aggregate
intrinsic
value
 
                     
$ thousands
 
                         
Outstanding at beginning of year
   
5,625,482
     
2.71
     
3.66
     
300
 
Granted
   
1,047,103
     
2.72
                 
Exercised
   
(2,088,940
)
   
2.83
                 
Forfeited or expired
   
(860,359
)
   
3.24
                 
                                 
Outstanding at end of the year
   
3,723,286
     
2.52
     
4.06
     
8,005
 
                                 
Options exercisable at end of the year
   
1,532,257
     
2.57
     
3.43
     
3,216
 
                                 
Vested and expected to vest
   
3,339,251
     
2.53
     
3.96
     
7,143
 
Schedule of RSUs Granted
   
Year ended December 31, 2024
 
   
Number of RSUs
   
Weighted average
fair value
 
             
             
Unvested at beginning of year
   
2,622,195
     
2.42
 
Granted
   
1,188,827
     
2.55
 
Vested
   
(885,664
)
   
2.54
 
Forfeited
   
(202,316
)
   
2.43
 
                 
Unvested at end of the year
   
2,723,042
     
2.43
 
Schedule of Equity-Based Compensation Expense
   
Year ended December 31,
 
   
2024
   
2023
   
2022
 
   
$ thousands
   
$ thousands
   
$ thousands
 
                   
Cost of revenues
   
495
     
482
     
587
 
Research and development, net
   
701
     
828
     
405
 
Sales and marketing
   
1,355
     
1,416
     
1,355
 
General and administrative
   
1,747
     
1,238
     
1,213
 
                         
Total share-based compensation expenses
   
4,298
     
3,964
     
3,560